Silvia Farinas-Calabuig

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Clinicopathological Study of a Series of Melanomas With IDH1 Mutation.

Clinicopathological Study of a Series of Melanomas With IDH1 Mutation.

Journal: The American Journal of dermatopathology
Published: March 27, 2026

Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy.

Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy.

Journal: The journal of liquid biopsy
Published: January 13, 2026

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.

Journal: NPJ precision oncology
Published: May 20, 2025

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.

Journal: Cancer letters
Published: March 18, 2025

Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions.

Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: February 28, 2025

Diagnostic and Prognostic Value of Angiogenic Status in Hereditary Hemorrhagic Telangiectasia.

Diagnostic and Prognostic Value of Angiogenic Status in Hereditary Hemorrhagic Telangiectasia.

Journal: Diagnostics (Basel, Switzerland)
Published: October 27, 2024

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients.

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients.

Journal: Scientific reports
Published: September 10, 2024

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

Journal: Cell death & disease
Published: February 21, 2024

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

Journal: Cell communication and signaling : CCS
Published: December 04, 2023

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer.

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences
Published: September 25, 2023

Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma.

Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma.

Journal: Molecular oncology
Published: May 05, 2023

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.

Journal: Nature communications
Published: April 26, 2023
Showing 1-12 of 52

Last Updated: 09/26/2026